FDA
-
-
-
-
-
-
-
Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease
-
-
-
-
-
-
-
Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021
-
-
-
-
-
-
-
Nicox First Quarter 2020 Business Update and Financial Highlights
-
-
-
-
-
-
-
Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma
-
-
-
-
-
-
-
Nicox Draws Down Last Tranche from Bond Financing Agreement with Kreos Capital to Support Key Development Programs
-
-
-
-
-
-
-
Nicox: First Half 2019 Financial Results and Business Update
-
-
-
-
-
-
-
Nicox to Present at Upcoming Pharmaceutical Industry and Financial Events
-
324,744 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

